Pipeline — registered trials by phase
Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002
— · Hereditary Angioedema · Enrolling By Invitation · est. 2040-04
Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001
— · Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy, Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy, Wild-Type Transthyretin Cardiac Amyloidosis · Enrolling By Invitation · est. 2038-03
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)
— · Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy, Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy, Wild-Type Transthyretin Cardiac Amyloidosis · Completed · est. 2025-09-12
NTLA-2002 in Adults With Hereditary Angioedema (HAE)
— · Hereditary Angioedema · Active Not Recruiting · est. 2024-04-04
HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)
— · Hereditary Angioedema · Active Not Recruiting · est. 2026-02-10
A Phase 3 Study of NTLA-2001 in ATTRv-PN
— · Neuromuscular Disease, Neuromuscular Diseases (NMD), Neurodegenerative Disease · Recruiting · est. 2027-07
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
— · Transthyretin Amyloidosis (ATTR) With Cardiomyopathy · Recruiting · est. 2027-12
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where Intellia is lead sponsor; 7 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- 8-K2026-09-08Current report (material event)
- 8-K2026-09-04Current report (material event)
- SCHEDULE 13G2026-08-07SCHEDULE 13G
- 10-Q2026-08-06Quarterly report
- 8-K2026-08-06Current report (material event)
- 8-K2026-06-15Current report (material event)
- 8-K2026-06-10Current report (material event)
- 10-Q2026-05-11Quarterly report
- 8-K2026-05-11Current report (material event)
- 8-K2026-04-30Current report (material event)
- ARS2026-04-30Annual report to holders
- DEFA14A2026-04-30DEFA14A
- DEF 14A2026-04-30Proxy statement
- SCHEDULE 13G2026-04-30SCHEDULE 13G
- 424B52026-04-29Prospectus (offering)
- SCHEDULE 13G2026-04-29SCHEDULE 13G
- 424B52026-04-27Prospectus (offering)
- 8-K2026-04-27Current report (material event)
- 8-K2026-04-10Current report (material event)
- SCHEDULE 13G/A2026-03-27SCHEDULE 13G/A
- 424B52026-03-02Prospectus (offering)
- 8-K2026-03-02Current report (material event)
- S-82026-02-26Employee stock plan
- 10-K2026-02-26Annual report
- 8-K2026-02-26Current report (material event)
- SCHEDULE 13G/A2026-02-12SCHEDULE 13G/A
- SCHEDULE 13G/A2026-02-11SCHEDULE 13G/A
- SCHEDULE 13G2026-02-09SCHEDULE 13G
- SCHEDULE 13G/A2026-02-03SCHEDULE 13G/A
- SCHEDULE 13G/A2026-01-30SCHEDULE 13G/A
- 8-K2026-01-27Current report (material event)
- 8-K2026-01-09Current report (material event)
- SCHEDULE 13G2025-11-12SCHEDULE 13G
- SCHEDULE 13G2025-11-12SCHEDULE 13G
- 8-K2025-11-10Current report (material event)
- 10-Q2025-11-06Quarterly report
- 8-K2025-11-06Current report (material event)
- SCHEDULE 13G/A2025-11-04SCHEDULE 13G/A
- 8-K2025-10-29Current report (material event)
- 8-K2025-10-27Current report (material event)
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.